Zealand Pharma is betting that artificial intelligence can help it design the next wave of obesity drugs.
The company announced a multi-target collaboration and license agreement with Generate Biomedicines on October 13, 2026. Total milestone payments could reach approximately $1.2 billion, plus tiered royalties on net sales.
Generate’s shares rose about 5% in after-hours trading following the news. For a company that only went public in February, that is a warm welcome to big pharma partnerships.
How the deal is structured
Zealand will pay Generate a $30 million upfront fee.
Beyond that, Generate is eligible for up to $35 million in preclinical milestone payments. These are cash rewards tied to hitting early research goals before any drug reaches a human trial.
Generate would also collect tiered royalties based on net sales from the initial programs.
The agreement covers two programs at the start. There is an option to add a third.
Who does what
Generate’s platform pairs generative design with high-throughput experimental validation. The company uses AI to propose new protein structures, then tests large numbers of them in the lab to see which ones actually work.
The goal is to pick lead candidates for multispecific protein therapeutics. These are molecules engineered to act on more than one biological target at the same time, which is useful in a condition as complex as obesity.
Once leads are selected, Zealand assumes responsibility for clinical development and regulatory submissions. It will also run worldwide commercialization of any resulting therapeutics.
Why Zealand wants this
The partnership fits into Zealand’s “Metabolic Frontier 2030” strategy. That plan aims to launch multiple programs by 2030 and push the company into new modalities.
Historically, Zealand’s core focus has been peptides. Bringing in multispecific proteins gives Zealand a way to diversify without building a protein design operation from scratch.
Zealand has more than 10 candidates in clinical development. Phase 2 data for petrelintide, one of its programs, has been described as promising.
Generate’s moment
Generate Biomedicines listed on Nasdaq on February 27, 2026. A partnership like this is exactly the kind of validation young public biotech companies hope to announce.
What this means
For Generate shareholders, the $30 million upfront payment is the concrete win. It brings in non-dilutive cash, meaning money that does not require issuing new shares.
Investors should watch for news on the optional third program. The preclinical milestones, worth up to $35 million, will be the first real scorecard.
For Zealand, obesity and metabolic disease treatment is a crowded and fiercely contested field, and differentiation increasingly comes from molecules that hit multiple targets. Partnering on multispecific proteins lets Zealand pursue that differentiation while keeping its core peptide programs, including petrelintide, moving forward.
Disclosure: This article was edited by Diego Almada Lopez. For more information on how we create and review content, see our Editorial Policy.